This is a preview of subscription content, log in via an institution to check access.
REFERENCES
R. Schlingensiepen, W. Brysch, and K.-H. Schlingensiepen. Antisense-From Technology to Therapy, Blackwell Science, Berlin, 1997.
A. Webb, D. Cunningham, F. Cotter, P. A. Clarke, F. di Stefano, P. Ross, M. Corbo, and Z. Dziewanowska. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet 349: 1137–1141 (1997).
F. Wong-Staal, E. M. Poeschla, and D. J. Looney. A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA. Hum. Gene Ther. 9:2407–2425 (1998).
S. T. Crooke. Vitravene-another piece in the mosaic. Antisense Nucleic Acid Drug Dev. 8:vii–viii (1998).
P. P. Chan and P. M. Glazer. Triplex DNA: Fundamentals, advances, and potential applications for gene therapy. J. Mol. Med. 75:267–282 (1997).
T. M. Woolf. Therapeutic repair of mutated nucleic acid sequences. Nat. Biotechnol. 16:341–344 (1998).
M. C. Rice, K. Czymmek, and E. B. Kmiec. The potential of nucleic acid repair in functional genomics. Nat. Biotechnol. 19:321–326 (2001).
S. M. Gryaznov. Oligonucleotide N3??P5? phosphoramidates as potential therapeutic agents. Biochim. Biophys. Acta 1489:131–140 (1999).
S. Agrawal and E. R. Kandimalla. Antisense therapeutics: Is it as simple as complementary base recognition? Molec. Med. Today 6:72–80 (2000).
K. Yoon, A. Cole-Strauss, and E. B. Kmiec. Targeted gene correction of episomal DNA in mammalian cells mediated by a chimeric RNA-DNA oligonucleotide. Proc. Natl. Acad. Sci. U S A 93:2071–2076 (1996).
P. Verspieren, A. W. C. A. Cornelissen, N. T. Thuong, C. Hélène, and J. J. Toulmé. An acridine-linked oligodeoxynucleotide targeted to the common 5? end of trypanosome mRNAs kills cultured parasites. Gene 61:307–315 (1987).
R. M. Crooke, M. J. Graham, M. J. Martin, K. M. Lemonidis, T. Wyrzykiewiecz, and L. L. Cummins. Metabolism of antisense oligonucleotides in rat liver homogenates. J. Pharmacol. Exp. Ther. 292:140–149 (2000).
E. Santana, A. E. Peritz, S. Iyer, J. Uitto, and K. Yoon. Different frequency of gene targeting events by the RNA-DNA oligonucleotide among epithelial cells. J. Invest. Dermatol. 111:1172–1177 (1998).
S. Ye, A. Cole-Strauss, B. Frank, and E. B. Kmiec. Targeted gene correction: A new strategy for molecular medicine. Molec. Med. Today 4:431–437 (1998).
S. Dheur, N. Dias, A. van Aerschot, P. Herdewijn, T. Bettinger, J. S. Remy, C. Helene, and E. T. Saison-Behmoaras. Polyethylenimine but not cationic lipid improves antisense activity of 3?-capped phosphodiester oligonucleotides. Antisense Nucleic Acid Drug Dev. 9:515–525 (1999).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Semir, D., Avinyó, A., Larriba, S. et al. Quantitative Assessment of Chimeraplast Stability in Biological Fluids by Polyacrylamide Gel Electrophoresis and Laser-Assisted Fluorescence Analysis. Pharm Res 19, 914–918 (2002). https://doi.org/10.1023/A:1016133722394
Issue Date:
DOI: https://doi.org/10.1023/A:1016133722394